18 stories mentioning NUVL
Every FINWIRES story that references NUVL, newest first.
Nuvalent (NUVL) has an average rating of hold and mean price target of $128.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of hold and mean price target of $128.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.
Nuvalent (NUVL) is fairly valued following GSK's (GSK) agreed acquisition of the company, with limited likelihood of a competing bid emerging, Wedbush Securities said in a Tuesday note.The brokerage said most logical strategic acquirers, including Pfizer (PFE), Roche and Bristol Myers Squibb (BMY), already have meaningful exposure to ALK- and ROS1-positive non-small cell lung cancer markets, making it difficult to justify a higher offer while achieving attractive returns.Wedbush said the deal validates the value of differentiated precision oncology assets with advantages in efficacy, tolerability, resistance mutation coverage and CNS penetration.The investment firm downgraded Nuvalent to neutral from outperform and lowered its price target to $124 from $125, matching the agreed tender offer price from GSK.Shares of Nuvalent rose more than 39% in Tuesday afternoon trading.Price: $123.12, Change: $+34.63, Percent Change: +39.13%
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $123.08, Change: $+34.59, Percent Change: +39.08%
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $122.87, Change: $+34.38, Percent Change: +38.85%
Nuvalent (NUVL) has an average rating of overweight and mean price target of $141.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of overweight and mean price target of $141.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of Buy and mean price target of $141.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of buy and mean price target of $141.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of Buy and mean price target of $141.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Deborah Ann Miller, Chief Legal Officer, on May 28, 2026, sold 5,500 shares in Nuvalent (NUVL) for $593,101. Following the Form 4 filing with the SEC, Miller has control over a total of 59,634 Class A common shares of the company, with 59,634 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1861560/000186874126000004/xslF345X05/ownership.xml
Darlene Noci, Chief Development Officer, on May 28, 2026, sold 5,500 shares in Nuvalent (NUVL) for $592,923. Following the Form 4 filing with the SEC, Noci has control over a total of 58,117 Class A common shares of the company, with 58,117 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1861560/000186214826000005/xslF345X05/ownership.xml
Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% lower and the iShares Biotechnology ETF (IBB) up 0.5%.Guardant Health (GH) shares were up more than 5% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.TG Therapeutics' (TGTX) Phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure between the approved two-infusion initiation regimen for Briumvi and a proposed single Day 1 infusion dosing schedule, the company said. TG Therapeutics stock was up more than 1% pre-bell.Nuvalent (NUVL) shares were up more than 1% after the company said the US Food and Drug Administration accepted for filing its New Drug Application for neladalkib, an investigational ALK-selective inhibitor in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.
Darlene Noci, Chief Development Officer, on April 29, 2026, sold 5,500 shares in Nuvalent (NUVL) for $547,524. Following the Form 4 filing with the SEC, Noci has control over a total of 58,117 Class A common shares of the company, with 58,117 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1861560/000119312526201549/xslF345X05/ownership.xml
Deborah Ann Miller, Chief Legal Officer, on April 30, 2026, sold 5,500 shares in Nuvalent (NUVL) for $545,691. Following the Form 4 filing with the SEC, Miller has control over a total of 59,634 Class A common shares of the company, with 59,634 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1861560/000119312526201555/xslF345X05/ownership.xml